Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.
about
Cytokines as biomarkers of nanoparticle immunotoxicityInteractions of nanomaterials and biological systems: Implications to personalized nanomedicinePolymeric Nanostructures for Imaging and TherapyPharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenograftsMacromolecular therapeuticsCurrent status of maintenance therapy for advanced ovarian cancer.Microbial biosynthesis of polyglutamic acid biopolymer and applications in the biopharmaceutical, biomedical and food industries.Polymer-drug conjugates: recent development in clinical oncologyProcoagulant inhibitory properties of paclitaxel poliglumex.Reversible exposure of hydrophobic residues on albumin as a novel strategy for formulation of nanodelivery vehicles for taxanes.RAFT-synthesized graft copolymers that enhance pH-dependent membrane destabilization and protein circulation timesMultifunctional synthetic poly(L-glutamic acid)-based cancer therapeutic and imaging agents.Polymer conjugates as anticancer nanomedicines.Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer.Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer.Anticancer carrier-linked prodrugs in clinical trials.Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate.Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates.Clinically relevant anticancer polymer Paclitaxel therapeutics.Lung cancer and women.A novel method for imaging in vivo degradation of poly(L-glutamic acid), a biodegradable drug carrier.Treatment of performance status 2 patients with advanced non-small-cell lung cancer: what we know and what we don't know.Polymer-drug conjugates for novel molecular targets.Recent advances in microbial biopolymer production and purification.Polymeric materials for theranostic applications.Potential environmental implications of nano-enabled medical applications: critical review.Ceramic nanoparticles: Recompense, cellular uptake and toxicity concerns.HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines.Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment.
P2860
Q28383550-7BD282E3-8D7B-4399-9E7A-BE150BF5D9C5Q28391849-E4FF16F0-72F4-4A4E-903E-BA71117C59B0Q30372383-39E6676C-A4C6-42BE-AFAB-F6BE5CCBF557Q33554366-6A6B9CC3-5DF7-4C63-A905-F701D3441B11Q34079574-1C206BEC-5A8F-44E4-AA2B-EA78EC01FCB4Q34271924-605199B8-F9C1-463E-825D-C1DDF8FFD9EAQ34653663-CAB3AD3D-87C0-4A7D-85B3-3389DD70C5D4Q34656003-A7FDF352-9D77-4EC3-82CB-D0FC8D051563Q34665903-A3DE97C6-4C90-4F3C-B16C-0A380F66E797Q35143239-F78D2101-7038-426A-B6B2-1722AEA5448EQ35739852-3AA10E40-3512-4718-A6B3-FDF6BBA76AEAQ36214907-468893F2-2CE9-4E72-A051-A3A1339EFE04Q36561667-17E48054-192B-4057-B507-B02027343537Q36667452-CA15F24C-E242-4B18-B4D2-AEE0170545C5Q36788450-CB80DFE2-4217-429C-894A-75A9B4FAB64BQ36861603-B3FA8617-02F9-416A-B2D8-AC30CD6D261DQ36920312-5E3DB5AB-A65E-470D-82F6-D80AE2066E24Q37096500-9FC8BF04-4B29-4B84-9AA1-8B5B36E2169EQ37129736-A0568933-AE7B-423F-BED9-59E2FC695DB8Q37298672-3CB432EF-42FD-4900-A861-D90DC3332F37Q37353124-CE015EB6-34A6-4702-AD7C-10B7DF4E4AC9Q37575622-86DC21F2-403B-40B4-9281-343DC520494BQ37782076-494D2173-2A8D-4CC1-A1D7-25CEABAC1745Q38063342-97CBDBCC-ACF2-4332-AF8F-781542E2A44CQ38114360-69E22DBE-0B11-443F-802B-BB3427C26A2BQ38193126-7A7572BE-5D2D-4FB6-BAFB-69109673AA9CQ38250374-33685D9F-0A20-4AB3-B64A-AD2029E3BC78Q40342855-20AFC012-FD18-4755-9AA3-00B5AFC85EEAQ52707854-9D78851B-A4A5-481C-9368-271F128B92D7
P2860
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.
@ast
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.
@en
type
label
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.
@ast
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.
@en
prefLabel
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.
@ast
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.
@en
P2093
P1433
P1476
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane
@en
P2093
Alberto Bernareggi
Brian Baker
Drew Nienstedt
Marc Besman
Scott Shaffer
Scott Stromatt
P304
P356
10.1097/00001813-200503000-00003
P577
2005-03-01T00:00:00Z